Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
Sign Up to like & getrecommendations! Published in 2022 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2022.101582
Abstract: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) were widely used in advanced non-small cell lung cancers (NSCLCs) with EGFR sensitive mutation and greatly improved the patient survival. With the widespread use of EGFR… read more here.
Keywords: cis c797s; combination; cis; therapy ... See more keywords